Anti-müllerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies.
Hum Reprod
; 23(3): 674-8, 2008 Mar.
Article
en En
| MEDLINE
| ID: mdl-18216040
ABSTRACT
BACKGROUND:
In female cancer survivors, the accelerated loss of primordial follicles as a result of gonadal damage may lead to premature ovarian failure (POF). However, the extent of the damage is unpredictable. Anti-Müllerian hormone (AMH) constitutes a sensitive marker of ovarian reserve. Serum AMH levels were measured to assess sub-clinical ovarian damage in patients treated with gonadotoxic therapy.METHODS:
In 25 patients with haematological malignancies, serum AMH concentrations were measured prior to and after cancer therapy and were compared with normo-ovulatory controls.RESULTS:
In all patients, AMH concentrations were lower than controls prior to treatment. Thirteen patients were treated with multi-drug chemotherapy. Although in most patients treated with chemotherapy menstrual cyclicity was restored, median serum AMH levels were lower than in controls. Twelve patients had stem cell transplantation (SCT) after total body irradiation. They all developed POF and their serum AMH concentrations were undetectable.CONCLUSIONS:
Female cancer survivors treated with SCT all developed POF. Hence, in these patients fertility preservation should be considered. In patients treated with chemotherapy, ovarian reserve seems to be compromised as well.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Ovario
/
Biomarcadores
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Irradiación Corporal Total
/
Insuficiencia Ovárica Primaria
/
Neoplasias Hematológicas
/
Trasplante de Células Madre
/
Hormona Antimülleriana
Tipo de estudio:
Diagnostic_studies
Límite:
Adolescent
/
Adult
/
Female
/
Humans
Idioma:
En
Revista:
Hum Reprod
Asunto de la revista:
MEDICINA REPRODUTIVA
Año:
2008
Tipo del documento:
Article
País de afiliación:
Países Bajos